At the Nebraska Cancer Research Center in Lincoln, NE, we are committed to providing people local access to cutting-edge cancer research through clinical trials.
Since our inception, thousands of volunteers have participated in treatment, prevention and control trials, helping us identify more effective cancer treatments and improve the lives of cancer patients.
The Nebraska Cancer Research Center
The Nebraska Cancer Research Center has been a leader in cutting-edge cancer research since 1984. At NCRC, we provide local access to clinical trials sponsored by the National Cancer Institute. Since our inception, thousands of volunteers have participated in treatment, prevention and control trials through NCRC, helping us identify more effective cancer treatments and improve the quality of life for cancer patients.
Thank you to everyone that attended the Nebraska Cancer Research Center's 3rd Annual “Colors of Hope: Cancer Research Fundraiser” on August 25, 2016! Nearly $22,000 was raised to support our efforts in providing local access to cutting edge research!
New Clinical Trials
ACCRU BI1199.52: A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.
RU011201l: A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
RU0214071: Regorafenib Dose Optimization Stuy (ReDos): A Phase II Randomized Study of Lower Dose Regorafenib compared to Standard Dose Regorafenib in Patients with Refractory Metastatic Colorectal Cancer
EA6134: Advanced Mutant Melanoma - A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma.
Alliance A031201: Metastatic Prostate Cancer - Phase III Trial of Enzalutamide Versus Enzalutamide, Abiraterone and Prednisone for castration resistant metastatic prostate cancer.